Coherus BioSciences (CHRS) Misses Q1 EPS by 205c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.37 +1.48%
EPS Growth %: +39.4%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: +39.4%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.35), $2.05 worse than the analyst estimate of $1.70. Revenue for the quarter came in at $7.6 million versus the consensus estimate of $54.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
- Vicor raises Q3 2026 revenue guidance on new licensing deal
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
